31 related articles for article (PubMed ID: 10944377)
1. Current State and Opportunities with Long-acting Injectables: Industry Perspectives from the Innovation and Quality Consortium "Long-Acting Injectables" Working Group.
Bauer A; Berben P; Chakravarthi SS; Chattorraj S; Garg A; Gourdon B; Heimbach T; Huang Y; Morrison C; Mundhra D; Palaparthy R; Saha P; Siemons M; Shaik NA; Shi Y; Shum S; Thakral NK; Urva S; Vargo R; Koganti VR; Barrett SE
Pharm Res; 2023 Jul; 40(7):1601-1631. PubMed ID: 36811809
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis.
Kapralos I; Dokoumetzidis A
Pharmaceutics; 2021 Sep; 13(10):. PubMed ID: 34683871
[TBL] [Abstract][Full Text] [Related]
3. Formulation and performance characterization of radio-sterilized "progestin-only" microparticles intended for contraception.
Puthli S; Vavia P
AAPS PharmSciTech; 2009; 10(2):443-52. PubMed ID: 19381829
[TBL] [Abstract][Full Text] [Related]
4. In vivo release kinetics of octreotide acetate from experimental polymeric microsphere formulations using oil/water and oil/oil processes.
Murty SB; Wei Q; Thanoo BC; DeLuca PP
AAPS PharmSciTech; 2004 Sep; 5(3):e49. PubMed ID: 15760082
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release delivery of octreotide from biodegradable polymeric microspheres.
Rhee YS; Sohn M; Woo BH; Thanoo BC; DeLuca PP; Mansour HM
AAPS PharmSciTech; 2011 Dec; 12(4):1293-301. PubMed ID: 21948321
[TBL] [Abstract][Full Text] [Related]
6. Nonparametric analysis of the absorption profile of octreotide in rabbits from long-acting release formulation OncoLAR.
Comets E; Mentré F; Nimmerfall F; Kawai R; Mueller I; Marbach P; Vonderscher J
J Control Release; 1999 May; 59(2):197-205. PubMed ID: 10332054
[TBL] [Abstract][Full Text] [Related]
7. Extended release microparticle-in-gel formulation of octreotide: Effect of polymer type on acylation of peptide during in vitro release.
Vaishya RD; Mandal A; Patel S; Mitra AK
Int J Pharm; 2015 Dec; 496(2):676-88. PubMed ID: 26561725
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method.
Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Schwendeman SP
Drug Deliv Transl Res; 2022 Mar; 12(3):695-707. PubMed ID: 34215997
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres.
Shi L; Caulfield MJ; Chern RT; Wilson RA; Sanyal G; Volkin DB
J Pharm Sci; 2002 Apr; 91(4):1019-35. PubMed ID: 11948541
[TBL] [Abstract][Full Text] [Related]
10. Modeling the kinetics of release of octreotide from long-acting formulations injected intramuscularly in rabbits.
Comets E; Mentré F; Kawai R; Nimmerfall F; Marbach P; Vonderscher J
J Pharm Sci; 2000 Sep; 89(9):1123-33. PubMed ID: 10944377
[TBL] [Abstract][Full Text] [Related]
11. Protein instability in poly(lactic-co-glycolic acid) microparticles.
van de Weert M; Hennink WE; Jiskoot W
Pharm Res; 2000 Oct; 17(10):1159-67. PubMed ID: 11145219
[TBL] [Abstract][Full Text] [Related]
12. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues.
Crotts G; Park TG
J Microencapsul; 1998; 15(6):699-713. PubMed ID: 9818948
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
